The Daily Buyout
~$1.5BreportedStrategic acquisitionHealthcare & Life SciencesCompleted

Repligen completes acquisition of BioLife Solutions

Repligen Corporation has closed its previously announced acquisition of Nasdaq-listed BioLife Solutions, a developer of cell processing tools and biopreservation media for the cell and gene therapy market. BioLife's CryoStor-led portfolio supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials, adding what Repligen calls a high-margin consumables business with recurring revenue to its bioprocessing lineup.

Why it matters: The deal pushes Repligen deeper into cell and gene therapy workflows, a growth pocket of life sciences tools where embedded consumables command durable revenue.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals

$5.8BTake-privateHealthcare & Life SciencesOct 7, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

Read at SEC EDGARFree
$2BStrategic acquisitionHealthcare & Life SciencesOct 6, 2026

Shionogi pays $2B for rare disease biotech IntraBio

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.

Read at BioPharma DiveFree